Sam Brusco, Associate Editor10.12.22
Synaptive Medical, a firm specializing in surgical planning, navigation, and robotic visualization technologies, began a joint-development partnership with bioelectronic medicine company Panaxium to merge Panaxium’s flexible iontronic electrocorticography (ECoG) platform with Synaptive’s Modus V robotic exoscope tech.
The integration will allow real-time intelligence about bioelectrical connections and functional mapping info during procedures to help preserve important brain tissues during resection, reduce duration, and boost post-surgery outcomes.
“Synaptive is proud to launch this research effort with extraordinary clinical partners advancing state-of-the-art in neurology and neurosurgery at renowned centres worldwide,” Cameron Piron, president and co-founder of Synaptive Medical told the press. “Synaptive already provides automated tractography segmentation for surgical planning with our imaging system, so the integration of Panaxium’s electrocorticography into Modus V is a natural next step for our technology and an exciting leap forward in the neurosurgical space.”
Panaxium’s recent development of more sensitive iontronic neural interfaces that exploit organic ion-conducting materials have provided the neuroscience research community with many clinically relevant insights by enabling much higher resolution mapping than conventional systems.
The benefits of this co-development partnership will be demonstrated in an upcoming pilot trial at hospitals in Paris, sponsored by INSERM, the French National Institute of Health and Medical Research and led by neurologist and researcher Dr. Gilles Huberfeld, MD, Ph.D. at the Hôpital Fondation Adolphe de Rothschild and INSERM.
“The ability to build up pathological biomarker maps with micro-resolution electrocorticography over large areas of the cortex is a huge step forward for clinical research,” said Dr. Huberfeld. “The alignment of ultra-precise electrophysiological information with a patient’s surgical planning information in real-time makes the Synaptive-Panaxium solution the ultimate neuro-navigation tool for brain surgery.”
Panaxium is also commercializing its iontronic interfaces for monitoring and therapeutic neurostimulation applications, including tumor resection procedures and stroke recovery treatments with proprietary AI-assisted software.
“This tool provides a level of electrophysiology information that has never been accessible during procedures before,” said Dr. Pierre Leleux, Ph.D., Panaxium co-founder and chief product officer. “The extraordinary and unprecedented data we are collecting then enables software intelligence for an expanding range of procedures that would benefit from cortical mapping, including neuropsychiatric, neuro-oncology, and neurodegenerative.”
The integration will allow real-time intelligence about bioelectrical connections and functional mapping info during procedures to help preserve important brain tissues during resection, reduce duration, and boost post-surgery outcomes.
“Synaptive is proud to launch this research effort with extraordinary clinical partners advancing state-of-the-art in neurology and neurosurgery at renowned centres worldwide,” Cameron Piron, president and co-founder of Synaptive Medical told the press. “Synaptive already provides automated tractography segmentation for surgical planning with our imaging system, so the integration of Panaxium’s electrocorticography into Modus V is a natural next step for our technology and an exciting leap forward in the neurosurgical space.”
Panaxium’s recent development of more sensitive iontronic neural interfaces that exploit organic ion-conducting materials have provided the neuroscience research community with many clinically relevant insights by enabling much higher resolution mapping than conventional systems.
The benefits of this co-development partnership will be demonstrated in an upcoming pilot trial at hospitals in Paris, sponsored by INSERM, the French National Institute of Health and Medical Research and led by neurologist and researcher Dr. Gilles Huberfeld, MD, Ph.D. at the Hôpital Fondation Adolphe de Rothschild and INSERM.
“The ability to build up pathological biomarker maps with micro-resolution electrocorticography over large areas of the cortex is a huge step forward for clinical research,” said Dr. Huberfeld. “The alignment of ultra-precise electrophysiological information with a patient’s surgical planning information in real-time makes the Synaptive-Panaxium solution the ultimate neuro-navigation tool for brain surgery.”
Panaxium is also commercializing its iontronic interfaces for monitoring and therapeutic neurostimulation applications, including tumor resection procedures and stroke recovery treatments with proprietary AI-assisted software.
“This tool provides a level of electrophysiology information that has never been accessible during procedures before,” said Dr. Pierre Leleux, Ph.D., Panaxium co-founder and chief product officer. “The extraordinary and unprecedented data we are collecting then enables software intelligence for an expanding range of procedures that would benefit from cortical mapping, including neuropsychiatric, neuro-oncology, and neurodegenerative.”